The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
Open accessAbstract
OBJECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses. METHODS: A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients). RESULTS: In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)₉₅(%) 0.51-0.74; intention to treat (ITT) P=0.031, CI₉₅(%) 0.47-0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI₉₅(%) 0.51-0.74; ITT P=0.046, CI₉₅(%) 0.47-0.69) and in rectal bleeding (PP P=0.014, CI₉₅(%) 0.46-0.70; ITT P=0.036, CI₉₅(%) 0.41-0.65), whereas stool frequency (PP P=0.202, CI₉₅(%) 0.39-0.63; ITT P=0.229, CI₉₅(%) 0.35-0.57), physician's rate of disease activity (PP P=0.088, CI₉₅(%) 0.34-0.58; ITT P=0.168, CI₉₅(%) 0.31-0.53), and endoscopic scores (PP P=0.086, CI₉₅(%) 0.74-0.92; ITT P=0.366, CI₉₅(%) 0.66-0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI₉₅(%) 0.36-0.60; ITT P=0.132, CI₉₅(%) 0.33-0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects. CONCLUSIONS: VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In IBD, the probiotic mixture VSL#3, which contains bifidobacteria of different species, was able to reduce the UC symptoms in adults (144, 145) as well as the remission of the disease in children (84).”
From Bifidobacteria and Their Health-Promoting Effects (2017) · cites this paper as [145]
In the citing paper
“Both demonstrate that high doses improve disease activity scores”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Kornbluth, A. A., & Sachar, D. B. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,032
Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G., Poggioli, G., Miglioli, M., & Campieri, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.9370 · Cited by 1,485
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,226
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Rembacken, B., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,100
Probiotic bacteria enhance murine and human intestinal epithelial barrier function
Madsen, K., Cornish, A. S., Soper, P., McKaigney, C. J., Jijon, H. B., Yachimec, C., Doyle, J. S. G., Jewell, L. D., & Simone, C. D. (2001) · Gastroenterology · doi:10.1053/gast.2001.27224 · Cited by 1,096
Kruis, W., SCHÜTZ, E., Fric, P., Fixa, B., Judmaier, G., & Stolte, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 774
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–489 of 489
Hoffman, R. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-30730-1_24 · Cited by 1
Friedrich, J. A. C. V., & de Fariña, L. O. (2020) · Brazilian Journal of Health Review · doi:10.34119/bjhrv3n6-193 · Cited by 1
Gastrointestinal Permeability After Bariatric Surgery: A Systematic Review
O’Brien, J., Merali, N., Pring, C. M., Rockall, T. A., Robertson, D., Bartlett, D. B., & Frampton, A. E. (2024) · Cureus · doi:10.7759/cureus.60480 · Cited by 1
“There is evidence that modifying the endotoxaemic process, for example, treatment with antibiotics or probiotics, can improve metabolic dysfunction; reduce colonic LPS [99], induce remission and improve dysbiosis [100,101] and reduce disease activity in IBD [102].”
BackgroundImpact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon
Tursi, A., Mocci, G., Usai–Satta, P., & Elisei, W. (2024) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871308652240712101604 · Cited by 1
Self-citationHart, D. W., Ng, A. S., Gazińska, P., Goldin, R. D., Gopal, P., O’Dell, N., Zargar, A., Pytowski, L., Montazid, S., Bardella, C., et al. (2026) · The Journal of Pathology · doi:10.1002/path.70034 · Cited by 1
“#3 to the conventional treatment of ulcerative colitis patients results in more ef fi cacious remission [101 – 103].”
Pastras, P., Aggeletopoulou, I., Psalti, V., & Triantos, C. K. (2026) · Pharmaceuticals · doi:10.3390/ph19050783 · Cited by 2
“A double-blind, randomized, placebo-controlled study showed that a high dose of VSL#3, used as an adjunct to mesalamine, significantly increased remission rates compared with placebo [78].”
Microbial shifts in early life: the pediatric gut microbiome and its role in health and disease
Waghmode, S., Viswanathan, R., Koligudde, V., Umare, P., & Lavania, M. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2681763 · Cited by 1
“146 147-149”
Bajoudah, R., Li, L., & Hussain, M. A. (2026) · Microorganisms · doi:10.3390/microorganisms14061360 · Cited by 1
Guy, J., del, S., Lima, F. A., Zurita-Turk, M., Miyoshi, A., Azevedo, V., & de LeBlanc, A. D. M. (2012) · InTech eBooks · doi:10.5772/26200 · Cited by 1
“#3 as adjunctive to a standard pharmaceutical treatment (Tursi et al., 2010) are required to confirm animal data and are necessary to convince the medical and general community of the benefits and potential application of probiotics in the prevention and treatment of IBD.”
BackgroundMethodThe Effect of Probiotics in Ulcerative Colitis
Lee, K. H., & Choi, C. H. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.60.2.67 · Cited by 1
Navigating the complexity of ulcerative colitis: challenging case example.
Lees, M., Regier, L. D., & Jensen, B. (2011) · PubMed Central · Cited by 1
The emerging therapy with probiotics in the management of inflammatory bowel disease: current status
Kumar, R., & Singh, J. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130803 · Cited by 1
Probiotics and Inflammatory Bowel Diseases
Lomangino, K. (2013) · Clinical Nutrition INSIGHT · doi:10.1097/01.nmd.0000434458.34301.16 · Cited by 1
Good Bacteria and Worms: As Promising Candidates for Inflammatory Bowel Disease
Ghalehnoei, H., Akhtari, J., Kalani, H., & Fakhar, M. (2018) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Das, K., Upadhyay, S., & Oli, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99988-5.00021-8 · Cited by 2
Benefits and safety of probiotics in gastrointestinal diseases
Profir, M., Roşu, O. A., Ionescu, R. F., Pavelescu, L. A., & Creţoiu, S. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824472-2.00011-7 · Cited by 1
Evidence-Based Complementary Therapies for the Management of Ulcerative Colitis
Kondreddy, V. K. R., Gadiraju, B., & Magisetty, J. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007705 · Cited by 1
Prävention und Therapie von entzündlichen Magen‐/Darm‐Erkrankungen
Stein, J. M., & Dignass, A. U. (2012) · Pharmazie in unserer Zeit · doi:10.1002/pauz.201100460 · Cited by 1
Bol, S., Talero, E., & S, V. M. (2015) · Ciencia e Innovación en Salud · doi:10.17081/innosa.3.1.239 · Cited by 1
The Role of Pre- and Probiotics in the Treatment of Inflammatory Bowel Disease
Triantafillidis, J. K. (2011) · Journal of Microbial & Biochemical Technology · doi:10.4172/1948-5948.s1-005 · Cited by 1
“4%) [32].”
Probiotics, Prebiotics, and Antibiotics in IBD
Gionchetti, P., Calabrese, C., Calafiore, A., & Rizzello, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-33703-6_46 · Cited by 1
Hospido, N. F., Cardelle‐Cobas, A., López, P. R., Sáez, A. C., & Sampayo, C. F. (2017) · Farmacéuticos Comunitarios · doi:10.5672/fc.2173-9218.(2017/vol9).001.03 · Cited by 2
Novel Approaches for Pouchitis and Colitis With or Without Diversion
Shen, J., & Guo, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809402-0.00043-5 · Cited by 1
Genomic Analysis of Lactic Acid Bacteria and Their Applications
Chen, W., & Gu, Z. (2018) · Springer eBooks · doi:10.1007/978-981-13-1559-6_2 · Cited by 1
Mining Human Microbiome for Therapeutics
Ghattargi, V. C., Sape, K., Kumbhare, S. V., & Shouche, Y. S. (2019) · Springer eBooks · doi:10.1007/978-981-13-8315-1_18 · Cited by 1
Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease
Gionchetti, P., & Rizzello, F. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0998-4_43 · Cited by 1
Probiotics in Inflammatory Bowel Disease
Mardini, H. E., & Grigorian, A. Y. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000040 · Cited by 1
“Surprisingly (may be not), the results of the latter were less impressive with only 43% remission rate compared with 80% in the earlier study.(2,3) Miele et al used a weight-based dose in pediatric patients who received concomitant systemic steroids as part of their induction regimen, and all patients in the study att…”
ResultWalsham, A. D. S. (2016) · UEA Digital Repository (University of East Anglia) · Cited by 1
On the Cost‐effectiveness of the Use of Probiotics in Inflammatory Bowel Disease
Samnaliev, M., & Lightdale, J. R. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31822ada65 · Cited by 1
Kafsi, H. E. (2014) · theses.fr (ABES) · doi:10.70675/c3ef71e9z2564z4f3fza520z4e48023240b0 · Cited by 1
The role of nitric oxide in the gastrointestinal tract
Gillberg, L. (2012) · Figshare
Short chain fatty acids (butyrate) for induction of remission in ulcerative colitis
Benharush, D., Cohen, M. J., Kasirer, Y. M., & Turner, D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008730
RetractedTherapie bei CED: Aminosalizylate, Steroide und Probiotika
Eigner, W., & Novacek, G. (2014) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Probiotics, Prebiotics, and Antibiotics for Ulcerative Colitis
Scott, F. I., & Aberra, F. N. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1677-1_18
INDIANA PHARMACISTS ALLIANCE (IPA) CONTINUING PHARMACY EDUCATION (CPE)
Patel, P. C., Williamson, M. A., Osborn, S. F., Lindsey, W. T., & Pharm, D. (2013)
VSL#3 Stimulates TCPTP and Attenuates IFN-gamma Induced Epithelial Barrier Permeability
Shah, N. N. (2013) · eScholarship (California Digital Library)
Correction of Microbiota Disturbances or Antagonism Against Specific Pathogens in IBD
Schiffrin, E. J., Marteau, P. R., & Brassart, D. (2014) · CRC Press eBooks · doi:10.1201/b16442-12
Principles of Medical Management of Ulcerative Colitis
Vu, H. T., & Dassopoulos, T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1677-1_4
The Different Drummer: Non-traditional Therapeutic Approaches
Yen, E. F. (2017) · Clinical gastroenterology · doi:10.1007/978-3-319-53763-4_12
Va, A., & Никонов, Е. Л. (2017) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro20176235-45
Microbes in Colon Cancer and Inflammatory Bowel Disease
Fong, I. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1670-2_2
Therapeutic Manipulation of Gut Microbiota
Ishiguro, E. E., Haskey, N., & Campbell, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-810541-2.00007-5
Use of probiotics and prebiotics in inflammatory bowel disease
Verma, S., Valcheva, R. S., Bakkari, S., & Dieleman, L. A. (2014) · doi:10.2217/ebo.13.543
Novel therapies for ulcerative colitis
Ben‐Horin, S., & Chowers, Y. (2013) · doi:10.2217/ebo.12.227
Rivas, M. A. (2018) · Human Biology
Omics technologies and the choice of treatment strategy for inflammatory intestinal diseases
Угаров, И. В., Смирнова, О. А., Lychkova, A. E., & Kostyuchenko, L. N. (2018) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro2018703118
“Опубликованы данные двух клинических испытаний с использованием многоцепочечного пробиотика VSL#3 для лечения неспецифического ЯК [159].”
Current Medical Therapies for Ulcerative Colitis
Cheah, M., & Khanna, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809402-0.00001-0
Feng, L., & Zhao, Y. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i6.367
Use of Probiotics, Prebiotics and Dietary Fibres in Inflammatory Bowel Disease
Silva, M. P. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3125qr85
Microbes in the Pathogenesis of Inflammatory Bowel Disease: A Review
Jatwani, S., Malhotra, B. K., Crout, T. M., & Majithia, V. (2019) · Springer eBooks · doi:10.1007/978-3-030-23311-2_37
Yokoyama, Y., Iida, T., & Nakase, H. (2019) · Open Journal of Gastroenterology and Hepatology · doi:10.28933/ojgh-2019-10-3106
Human Gut Microbiota: Friend or Foe?
Pliszka, M., & Szablewski, L. (2020) · OBM Hepatology and Gastroenterology · doi:10.21926/obm.hg.2003050
ESBL-producing Enterobacterales - Transmission, intestinal colonization and host response
Ljungquist, O. (2020) · Lund University Publications (Lund University)
国家の対外行動分析における国内要因--ネオクラシカル・リアリズムアプローチに向けての一考察
水沢, 紀. (2007) · 政治学研究論集
Mack, D. R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5061-0_29
Hospido, N. F., Cardelle‐Cobas, A., López, P. R., Sáez, A. C., & Sampayo, C. F. (2017) · Farmacéuticos Comunitarios · doi:10.5672/fc.2173-9218.(2017/vol1).001.03
Quigley, E. M. M. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734986666.793569667
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01703-0
Brüssow, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734986666.793562125
Mack, D. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-49215-5_28
Evidence on the risks and safety of probiotics for humans
Simone, C. D., & Marazzato, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89908-6.00021-2
Prebiotics, Probiotics, and Dietary Supplements
Dibba, P., Kothari, M., & Grosman, I. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-94953-2_11
Probióticos para el tratamiento de la Colitis Ulcerosa y la Enfermedad de CrohnPreprint
Aliaga, A. C., & Delgado-Diaz, D. J. (2022) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/9cpk3
Singh, J., Sharma, M., Mittal, A., Utreja, P., Singh, H., Kaur, P., & Kumar, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4177724
Vaezijoze, S., Irani, S., Siadat, S. D., & Zali, M. R. (2023) · فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران · doi:10.52547/iau.33.1.1
Adjuvant nutraceuticals in the management of gastrointestinal diseases
Balio, B. G., Giro, R., & Roriz, M. (2023) · Acta Portuguesa de Nutrição · doi:10.21011/apn.2023.3210
Dietary Intervention in Management and Remission of Ulcerative Colitis: A Systematic Review
Elias, A. A., Yerramsetti, M. D., Olanisa, O. O., Jain, P., Khan, Q. S., Vemulapalli, A. C., & Butt, S. R. (2023) · Journal For International Medical Graduates · doi:10.56570/jimgs.v2i2.136
“Promising options in this regard include VSL#3 and Lactobacillus reuteri [23].”
BackgroundA review of the use of probiotics in the treatment of ulcerative colitis
Ghaleh, H. E. G., & Bahrami, S. (2023) · Modern Medical Laboratory Journal · doi:10.30699/mmlj17.6.1.15
Does Neonatal Microbiome Research Encompass the Placental Transfer Pathway?
Choi, Y. (2023) · Neonatal Medicine · doi:10.5385/nm.2023.30.4.96
Role of Probiotics in Gut Micro-flora
Rai, S., Yadav, P., Debnath, N., Arora, S., & Yadav, A. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-6831-2_20
A systematic assessment on the influence of probiotics on patients with Inflammatory Bowel Disorder
Upadhye, V. J., Ballal, S., Singh, S., & Rani, R. (2024) · Multidisciplinary Reviews · doi:10.31893/multirev.2023ss022
Huerta, M. C. C. C., Antunez‐Mojica, M., Plascencia, H. M., & Molina, A. I. B. (2024) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2024.02.002
A Comprehensive Analysis of Efficacy and Safety of Probiotics in Inflammatory Bowel Disease
Abraamyan, F., & Misra, N. (2024) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2024.146024
Hart, D. W., Ng, A. S., Gazińska, P., Goldin, R. D., Gopal, P., O’Dell, N., Montazid, S., East, J. E., Tomlinson, I. P. M., Koch, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.05.658065
Microbiota, Prebiotics, Antibiotics, and Fecal Microbiota Transfer
Schauer, A. E., König, A., Nörenberg, J., Vogler, S., Steube, A., & Stallmach, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-87503-8_16
Guilcher, K., Pittet, V. E. H., Moser, A., Petit, L., Heyland, K., Braegger, C., Nydegger, A., Garzoni, L., Schibli, S., Spalinger, J. H., et al. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70252
“8,9 One well ‐ established dietary approach in pediatric CD is the use of exclusive enteral nutrition (EEN) for induction of remission.”
Rahi, A., Azizian, R., Mohammadi, M. R., Namadiyam, N., Azimi, A., & Hamidi, M. (2025) · The Open Microbiology Journal · doi:10.2174/01187428582701202627012026
Tan, H., Chen, M., Yao, H., Li, S., & Nie, S. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c09097 · Cited by 1
Jyonouchi, H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_120
Kang, S., Lin, Z., Xu, Y., Park, M., Ji, G., Johnston, T. V., Ku, S., & Park, M. S. (2022) · Figshare · doi:10.6084/m9.figshare.20026246
Immuno-Modulation Properties of Lactobacillus delbrueckii
Rocha, C. S. (2011) · theses.fr (ABES) · doi:10.70675/aec0ea62zd50dz47adzbbf9z3175e3e63a3e
Diet and complementary medicine in IBD: myths and realities
Crucillà, S., Mourad, F. H., & Hashash, J. G. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-103001
The Microbiome in the Development and Treatment of Inflammatory Bowel Disease
Zhetkenev, S., Konovalov, R., Akhmetkaliyev, A., & Sonnenberg-Riethmacher, E. (2026) · Biomedicines · doi:10.3390/biomedicines14081754
“[224], Lactobacillus delbrueckii and Lactobacillus fermentum [225] or EcN [226].”
Bacteriotherapy reintroduces “old friends” in IBD
Nanki, K., Naganuma, M., Mizuno, S., Matsuoka, K., & Kanai∥, T. (2015) · Inflammation and Regeneration · doi:10.2492/inflammregen.35.122
Probiotiques et maladies inflammatoires cryptogénétiques de l’intestin
Marteau, P. R., & Camus, M. (2011) · Phytothérapie · doi:10.1007/s10298-011-0614-9
Metadata
- Authors
- Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., Modeo, M. E., Rodino', S., D'Amico, T., Sebkova, L., Sacca', N., Di Giulio, E., Luzza, F., Imeneo, M., Larussa, T., Di Rosa, S., Annese, V., Danese, S., & Gasbarrini, A.
- Affiliations
- Ospedale L. Bonomo (IT)
- Ospedale Cristo Re (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliera Pugliese Ciaccio (IT)
- St. Eugenio Hospital (IT)
- Ospedale Santa Maria Goretti (IT)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Azienda Ospedaliero-Universitaria "Renato Dulbecco" (IT)
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Tursi, Antonio
- ORCID
- Venue
- American Journal of Gastroenterology
- Published
- 2010-10
- Volume
- 105
- Issue
- 10
- Pages
- 2218-2227
- ISSN
- 0002-9270 (ISSN-L)
- PMC
- PMC3180711
- OpenAlex
- W1998335236
- Cited by
- 489
- References
- 39
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 35 · 2023: 30 · 2022: 29 · 2021: 28 · 2020: 46 · 2019: 31 · 2018: 39 · 2017: 38 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 27 · 2012: 28
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (unspecified)
- Locations
- The American Journal of Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- ulcerative colitis, VSL#3, probiotics, adjunctive therapy, relapsing disease, 5-aminosalicylic acid, immunosuppressants, disease activity, rectal bleeding, stool frequency, inflammatory bowel disease treatment, pouchitis, Crohn's disease, irritable bowel syndrome, irritable bowel syndrome with diarrhea
- MeSH terms
- Adult, Azathioprine, Bifidobacterium, Colitis, Ulcerative, Combined Modality Therapy, Double-Blind Method, Female, Humans, Lactobacillus, Male, Middle Aged, Recurrence, Remission Induction, Severity of Illness Index, Treatment Outcome, Patient Selection, Mesalamine, Probiotics, Streptococcus thermophilus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
